Antitumor effects of hydroxycamptothecin-loaded poly[ethylene glycol]-poly[γ-benzyl-L-glutamate] micelles against oral squamous cell carcinoma

Oncology Research

Volumn 16, Issue 7, 2007, Pages 313-323

  Ding, Xue Qiang ^a   Chen, Dan ^a   Wang, An Xun ^a   Li, Su ^a   Chen, Yu ^a   Wang, Ji ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Amphiphilic block copolymer micelles; Hydroxycamptothecin (HCPT); Oral squamous cell carcinoma (OSCC); Poly ethylene glycol (PEG); Poly benzyl L glutamate (PBLG); Poorly soluble drugs

Indexed keywords

CAMPTOTHECIN DERIVATIVE; HYDROXYCAMPTOTHECIN; LACTONE; MACROGOL DERIVATIVE; POLY[ETHYLENE GLYCOL] POLY[GAMMA BENZYL LEVO GLUTAMATE]; SODIUM; UNCLASSIFIED DRUG; 10 HYDROXYCAMPTOTHECIN; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; POLY GAMMA BENZYL GLUTAMATE; POLY-GAMMA-BENZYL-L-GLUTAMATE; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXYLATION; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DIALYSIS; DRUG EFFECT; ENCAPSULATION; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MICELLE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; CHEEK; CHEMISTRY; FEMALE; HUMAN; IC 50; MALE; MOUTH MUCOSA; MOUTH TUMOR; PARTICLE SIZE; PATHOLOGY; TONGUE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEEK; CRICETINAE; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICELLES; MOUTH MUCOSA; MOUTH NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; TONGUE NEOPLASMS;

EID: 34250321637     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783980991     Document Type: Article

References (27)

1. Massano, J.; Regateiro, F. S.; Januario, G.; Ferreira, A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 102:67-76; 2006.
2. Chin, D.; Boyle, G. M.; Porceddu, S.; Theile, D. R.; Parsons, P. G.; Coman, W. B. Head and neck cancer: Past, present and future. Expert Rev. Anticancer Ther. 6:1111-1118; 2006.
3. Garcia-Carbonero, R.; Supko, J. G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8:641-661; 2002.
4. Fiorani, P.; Bjornsti, M. A. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. NY Acad. Sci. 922:65-72; 2000.
5. 14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma. World J. Gastroenterol. 11:5221-5225; 2005.
6. Wang, A. X.; Li, S.; Ding, X. Q.; Chen, Y.; Chen, D. Antitumor effects of ring-closed and ring-opened hydroxycamptothecin on oral squamous cell carcinoma cell line Tca8113. Chin J. Cancer 24:970-974; 2005.
7. Mallery, S. R.; Shenderova, A.; Pei, P.; Ciminieri, J. R.; Wilson, R. F.; Casto, B. C. Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous carcinoma regression model. Anticancer Res. 21:1713-1722; 2001.
8. Zhou, J. J.; Liu, J.; Bin, X. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol. Sin. 22:827-830; 2001.
9. Laco, G. S.; Du, W.; Kohlhagen, G.; Sayer, J. M.; Jerina, D. M.; Burke, T. G.; Curran, D. P.; Pommier, Y. Analysis of human topoisomerase I inhibition and interactions with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies. Bioorg. Med. Chem. 12:5225-5235; 2004.
10. Zhang, L.; Li, S.; Liao, H.; et al. Phase I trial of pharmacokinetics and human tolerability to 10-hydroxycamptothecin in patients with advanced malignancy. Chin. J. Cancer 20:1391-1395; 2001.
11. Mu, L.; Chrastina, A.; Levchenko, T.; Torchilin, V. P. Micelles from poly(ethylene glycol)-phosphatidyl ethanolamine conjugates (PEG-PE) as pharmaceutical carriers for poorly soluble camptothecin. J. Biomed. Nanotechnol. 1:190-195; 2005.
12. Torchilin, V. P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73:137-172; 2001.
13. Jones, M. C.; Leroux, J. C. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48:101-111; 1999.
14. Oh, I.; Lee, K.; Kwon, H. Y.; Lee, Y. B.; Shin, S. C.; Cho, C. S.; Kim, C. K. Release of adriamycin from poly(γ-benzyl-L-glutamate)/poly (ethylene oxide) nanoparticles. Int. J. Pharm. 181:107-115; 1999.
15. Yoo, H. S.; Park, T. G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release 70:63-70; 2001.
16. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv. Drug Delivery Rev. 47:113-131; 2001.
17. Chen, C.; Yu, C. H.; Cheng, Y. C.; Yu, P. H. F.; Cheung, M. K. Biodegradable nanoparticles of amphiphilic copolymers based on poly(3-hydroxybutyrate) and poly(ethylene glycol) as drug carriers. Biomaterials 27:4804-4814; 2006.
18. Li, S.; Jiang, W. C.; Wang, A. S.; et al. Studies on 5-FU/PEG-PBLG nanomicelles: Preparation, characteristics, and drug releasing in vivo. Chin. J. Cancer 23:381-385; 2004.
19. Maeda, H.; Wu, J.; Sawa, T.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65:271-284; 2000.
20. Torchilin, V. P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 61:2549-2559; 2004.
21. Li, S.; Jiang, W.; Wang, A.; et al. Releasing characterization, pharmacokinetics and distribution of PEG-PBLG co-polymer micelles in vitro and in vivo. Chin. Pharm. J. 9:699-702; 2005.
22. Zhang, R.; Li, Y.; Cai, Q.; Liu, T.; Sun, H.; Chambless, B. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharmacol. 41:257-267; 1998.
23. Shin, I. L.; Kim, S. Y.; Lee, Y. M.; Cho, C. S.; Sung, Y. K. Methoxy poly(ethylene glycol)/ε-caprolactone amphiphilic block copolymeric micelles containing indomethacin. I. Preparation and characterization. J. Control. Release 51:1-11; 1998.
24. Brigger, I.; Chaminade, P.; Marsaud, V.; Appel, M.; Besnard, M.; Gurny, R.; Renoir, M.; Couvreur, P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214:37-42; 2001.
25. Kim, S. Y.; Ha, J. C.; Lee, Y. M. Poly(ethylene oxide)-poly(propylene oxide)/poly-(epsiloncaprolactone) (PCL) amphiphilic block copolymeric nanospheres. II Thermo-responsive drug release behaviors. J. Control. Release 65:345-358; 2000.
26. Fassberg, J.; Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:676-684; 1992.
27. Savic, R.; Luo, L.; Eisenberg, A.; Maysinger, D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 200:615-618; 2003.